Category

Research Review
Research Review Multiple Myeloma Summit Highlights include:  High risk MM outcomes 5-year results for CyBorD MRD for guiding myeloma treatment Burden of MM in NZ Download here
Continue Reading
Issue 28 of Multiple Myeloma Research Review. Highlights include:  Elotuzumab monotherapy for smouldering MM Thereapetuc vulnerability of MM to Pri-17-92 inhibition Identification of novel mutational drivers reveals oncogene dependencies in MM Patient reported health-related Q0L from TOURMALINE-MM1 Download here
Continue Reading
Issue 27 of Multiple Myeloma Research Review Highlights include:  Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome. Loss of heterozygosity indicates homologous repair deficiency in MM. Treatment intensification with SCT + lenalidomide in new MM in CR. Download here
Continue Reading
Issue 26 of Multiple Myeloma Research Review. Highlights include:  Selinexor in relapsed/refractory multiple myeloma HIV antivirals overcome carfilzomib resistance in multiple myeloma Outcome and survival trends in multiple myeloma during 2008-2015 Bortezomib before and after high-dose therapy in multiple myeloma Download here
Continue Reading
ANZMAP Multiple Myeloma Highlights from ASH 2017 This publication provides summaries of key clinically relevant multiple myeloma data presented at the 59th ASH Annual Meeting and Exposition, 9–12 December 2017 in Atlanta, Georgia, USA. The Chair (Associate Professor Peter Mollee) and clinicians involved in the Australian and New Zealand Myeloma Ambassador Program (ANZMAP) selected the...
Continue Reading
Issue 25 of Multiple Myeloma Research Review.   Highlights include: Induction VCD. Prediction of outcome in newly diagnosed myeloma Final analysis of survival in the FIRST trial in MM. Daratumumab + VMP for untreated myeloma. Download here
Continue Reading
Issue 24 of Multiple Myeloma Research Review.   Highlights include: Is MRD the best predictor of response? ctDNA and risk of distant relapse. Cardiac safety of bortezomib. Cytogenic evolution in relapsed MM. Download here
Continue Reading
Issue 23 of Multiple Myeloma Research Review.   Highlights include: • Revised Myeloma Comorbidity index for multiple myeloma prognosis. • Genetic basis for zoledronic-acid related osteonecrosis of the jaw. • Front-line carfilzomib-containing regimens for multiple myeloma. • Multiple myeloma prognoses predicted by immunoglobulin recovery post-SCT.   Download here
Continue Reading
This publication is a summary of selected presentations delivered at the Haematology Society of Australia and New Zealand (HSANZ) Inaugural International Myeloma Summit Meeting held in Queenstown in August 2016. The exciting program featured two international speakers, Professor Paul Richardson from the Dana-Farber Cancer Institute, Boston and Professor Ola Landgren from the Memorial Sloan-Kettering Cancer...
Continue Reading
Issue 22 of Multiple Myeloma Research Review. Highlights include: •   Benefits of low dose lenalidomide in relapsed/refractory MM. •   Network meta-analysis: treatment outcomes in relapsed/refractory MM. •   Improved outcomes for patients treated a speciality MM clinics. •   Real world benefits of bortezomib regimens for non-transplant eligible MM. Download here
Continue Reading
1 2

Floor 7, 90 The Terrace
Wellington Central
New Zealand